Non-small cell lung cancer(NSCLC)with oncogenic driver mutations was previously deemed“forbidden territory”for immunotherapy.[1]With the continuous generation of evidence,immunotherapy is expected to bring hope for such NSCLC with oncogenic driver mutations after acquired tyrosine kinase inhibitor(TKI)resistance.However,given the intricate interplay between driven mutations,targeted therapy,and immune microenvironment,the efcacy of immunotherapy in advanced NSCLC patients with diverse oncogenic driver mutations remains a topic of ongoing debate.In this context,Chinese Expert Consensus on Immunotherapy for Advanced NSCLC with Oncogenic Driver Mutations(2022 edition)wasrst launched in 2022 by the Society of Cancer Precision Medicine of Chinese Anti-Cancer Association and the Lung Cancer Expert Group of Chinese Medical Journals,aiming to provide standardized treatment guidance for clinical practice.
The Society of Cancer Precision Medicine of Chinese Anti-Cancer Association;The Lung Cancer Expert Group of Chinese Medical Association Publishing House;Baohui Han;Hua Zhong;
Department of Respiratory Medicine,Shanghai Chest Hospital,School of Medicine,Shanghai JiaoTong University,Shanghai 20030,ChinaShanghai Chest Hospital,Shanghai Jiao Tong University School of Medicine
临床医学
immunotherapy;cancer;lung;
《Chinese Medical Journal》 2024 (009)
P.1016-1018 / 3
10.1097/CM9.0000000000003055
评论